Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKYSCRAPER-03: Atezolizumab + Tiragolumab vs Durvalumab After cCRT in Unresectable Stage III NSCLC
jRCT2080225327Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Aug 2020
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Atezolizumab + Tiragolumab with Durvalumab (2 arms). Started Aug 2020; status: completed.
02
Drugs
atezolizumabtiragolumabdurvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080225327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225327.